A multi-institutional study, drove by the Proceedings of the National Academy of Sciences journal, distinguished both the hereditary abnormalities that drive pr
Research finds association between genetic changes in head-neck cancer, immunotherapy resistance ANI | Updated: May 02, 2021 22:10 IST
Washington [US], May 2 (ANI): A multi-institutional study, drove by the Proceedings of the National Academy of Sciences journal, distinguished both the hereditary abnormalities that drive pre-cancer cells that lead to an intrusive kind of head and neckcancer and patients who are liable to react to immunotherapy to the least extent. Through a series of surprises, we followed clues that focused more and more tightly on specific genetic imbalances and their role in the effects of specific immune components in tumour development, said co-principal investigator Webster Cavenee, PhD, Distinguished Professor Emeritus at the University of California San Diego School of Medicine.
E-Mail
WASHINGTON - The Society for Cardiovascular Angiography and Interventions (SCAI) presented its Master Interventionalists of SCAI (MSCAI) designations during the SCAI 2020 Scientific Sessions Virtual Conference MSCAI recognition ceremony.
The MSCAI designation is awarded to individuals who have demonstrated excellence in invasive/interventional cardiology over the course of their career and for their commitment to the highest levels of clinical care, innovation, publication, and teaching.
This year s MSCAI designations were awarded to the following group of outstanding interventionalists:
Ian C. Gilchrist, MD, MSCAI
Dr. Ian C. Gilchrist is a professor of medicine for Penn State University s College of Medicine at the Hershey Medical Center in Hershey, PA. Dr. Gilchrist graduated from Dartmouth College in Hanover, NH and then obtained his medical degree from Columbia University. He received his residency and cardiology fellowship training at the St. Luke s/Roosevelt Hospi
Coronavirus update: Moderna promises more vaccine doses, new daily cases still under 60,000
Arkansas children are being infected by virus variants 04/29/2021
Total U.S. confirmed cases: 32,235,827 (32,179,505)
Total U.S. deaths: 574,383 (573,452)
Total global cases: 149,766,134 (148,859,866)
Total global deaths: 3,153,812 (3,138,755)
Moderna steps up vaccine production
Moderna, the maker of one of three approved coronavirus (COVID-19) vaccines used in the U.S., says it will spend up to $1 billion to increase production. It said it may triple its annual output of vaccine doses by next year.
Demand for vaccines in the U.S. has begun to decline slightly, but the rest of the world particularly India and Brazil are desperately in need of more doses. Moderna said the increase in production is aimed at meeting that need.
(1)
Collaborative mice study with UC San Diego to study brain development from embryo to old age
Berwyn, Pennsylvania (Newsfile Corp. - April 29, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer s disease (AD), Parkinson s disease (PD) and other neurodegenerative diseases, today announced a new research collaboration with Professor William Mobley and Dr. Xuqiao Chen at the University of California San Diego designed to study the ability of the Company s lead compound, ANVS401, to normalize brain development in Down Syndrome (DS) mice. While we know quite a bit about how the brain degenerates in the later stages of life, extraordinarily little is known about how neurodegeneration may start very early in life. We, therefore, plan to look at the brain in embryonic development in DS mice, said Maria Maccecchini, Ph.D., Founder and Chief Executive Officer.